DDR1/2 inhibition augments CD4+ and CD8+ T-cell infiltration through the suppression of IL-18 synthesis while reducing ECM stiffness, thereby prolonging the survival of tumor-bearing mice [178, 179]. Here, CD8A is linked to neoplasm.